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Public health genomics and the challenges for epidemiology
While chronic diseases (e.g. obesity,
diabetes, coronary heart disease,
cancer, etc), also named ‘complex dis-
eases’, are caused by the combined
effects of multiple environmental and
genetic factors, it is estimated that the
environmental component plays a major
role. Nevertheless, the smaller role of
inherited genetic factors may partly be
explained by the difficulties in exploring
this component until recently. The huge
amount of genomics data produced by
the fast-developing biotechnologies at
an unprecedented speed will probably
help in dissecting the genetics under-
lying these diseases.
During the past 5 years, genome-wide
association studies (GWAS) identified
hundreds of genomic loci robustly asso-
ciated with common chronic diseases.1
While this strategy has provided key
novel insight into disease biology within
a very short time scale, it will take many
years before the impact of GWAS
findings can be precisely estimated.
GWAS, as currently conducted, is not
able to identify rare variants, structural
variants (e.g. copy number variation),
and loci displaying high level of allelic
heterogeneity across populations be-
cause current standards require associ-
ations to be replicated in independent
populations. Hence, there is still a large
fraction of the trait heritability to be
explained, the so-called ‘missing herit-
ability’. The current application of mas-
sive parallel sequencing (MPS) is
identifying rare variants associated with
common chronic diseases. The huge
heterogeneity, almost at an individual
level, of the genetic alterations found
through these new technologies empha-
sizes the notion of individualized dis-
eases. Epidemiologists are now moving
the focus of their analyses from single
genetic variants to entire genes and/or
pathways.
Thinking on the biological meaning
of the genetic variants, there is probably
a continuum between rare monogenic
diseases with few loci exerting large
effects and common complex traits
with a large number of loci with tiny
effect sizes. Thus, most of the identified
genetic variants have very small effect
sizes and probably interact with other
genetic variants and with environmental
factors, though examples of robust and
validated interactions are still rare.1
Hence, most genetic variants identified
to date, when taken individually, are
neither necessary nor sufficient to cause
disease but they may have a direct effect
on intermediate outcomes such as gene
expression and/or protein function.
Accordingly, epidemiologists need to
deal with the design of large studies
aiming at integrating genetics, genomics,
transcriptomics and proteomics data
at the individual level, together with
extensive information on environmental
factors and behaviours.
Regarding the latter, epidemiologists
face the important challenge of assessing
the complexity of highly correlated en-
vironmental exposures. We do not have
platforms able to assess environmental
exposures with the same low measure-
ment error as ‘omics’ (in particular
genomics) platforms do. Rather, we
continue asking individuals about their
lifespan exposures through question-
naires, which represent soft data. Yet,
selected biomarkers represent excellent
tools to measure environmental expos-
ures with higher accuracy. A change
in paradigm is needed, moving from
a candidate to an agnostic/exploratory
exposure analysis. Incorporating epige-
nomics (i.e. modifications in DNA
methylation of CpG islands, histone
acetylation, etc) and metabolomics
markers should help in better dissecting
the still ‘missing exposurome’ for most
chronic diseases. Tools for standardized
collection across centres and across
countries will be needed to this end.
Furthermore, the notion that nothing
is static during an individual’s lifespan is
becoming more and more important.
The changes along the time apply to
environmental exposures and to ‘omics’
data. Taking such lifelong modifications
into account in epidemiological studies
is going to be a very difficult task that
will necessitate to closely monitor indi-
viduals. Once the data is available, its
modelling will represent another
challenge.
Following the current concept of
epidemiological study design and statis-
tical power requirements, very large
sample sizes are needed to explore the
underlying biological complexity in a
meaningful manner. Being provoca-
tive, we could argue that instead of
conducting large scale epidemiological
studies, epidemiologist should focus on
fewer extremely very well characterized
and bio-monitored individuals. In any
case, the integration of several types
of data, from environmental exposures
to epigenetics, metabolomics and gen-
omics, requires the development of
innovative bioinformatics and data re-
duction techniques. There is still a long
way to go.
The extraordinary development of
hypothesis-free (agnostic) approaches
should not discourage researchers from
conducting targeted candidate gene
studies. Both approaches should be
viewed as complementary and synergis-
tic. Similarly, although most GWAS
have included unrelated people, family-
based studies may bring valuable infor-
mation on transgenerational effects,
shared environmental factors and
parent-of-origin effects. An example
illustrating future challenges in terms
of study design can be found in the field
of pharmacogenomics that aims at iden-
tifying genetic variants involved in drug
response in order to improve drug safety
and efficacy, thus minimizing side ef-
fects. There are large inter-individual
variations in the activity of enzymes
involved in drug metabolism and trans-
port that are in large part genetically
determined. In contrast to the small
effect of the identified variants
associated with the risk of common
complex traits, the effect of
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pharmacogenomic-related variants may
be larger and clinically relevant. The
recently launched Clarification of
Optimal Anticoagulation through
Genetics (COAG) double-blind, rando-
mized controlled trial2 will ascertain
whether adapting the dose of warfarin
therapy based on genetic variants
located within the CYP2C9 and
VKORC1 genes may improve patient
care as compared with a
clinically-guided dosing algorithm.
Designing such a trial is particularly
challenging because the power to detect
a pre-specified between-group differ-
ence will depend on the genetic
makeup of the participants. The chal-
lenge comes from the fact that allele
frequencies may vary substantially
across ethnic groups. To recommend
genetic testing, investigators will need to
demonstrate that drug dosing based on
genetic information significantly re-
duces costs and morbidity.3
Focusing on a single disease or on a
single trait does not allow understanding
the full range of phenotypes associated
with many genes, for which pleiotropic
effects have been described (i.e. one
gene may be involved in both cancer
and cardiovascular disease). Hence, an
additional challenge for epidemiologists
is collecting extensive phenotypic data,
not only at a single point in time, but
longitudinally, again. The collection of
high quality phenotypes and more com-
prehensive phenomes are therefore of
utmost importance and will be key to
better account for the underlying bio-
logical complexity of human organisms
living in selected environmental condi-
tions.4,5 The digitalization of patient’s
records and imaging technologies, as
well as web-based testing, should allow
accumulating and linking massive
amounts of information for each
person. The availability of entire gen-
omes and phenomes may revolutionize
the way we classify diseases. There is little
doubt that data-gathering technology
has dramatically changed and will
continue to largely influence the way
epidemiologists conduct research.
Making best use of all the available
information, without harming study
participants (i.e. discrimination by in-
surance companies or employers, undue
access to the data by third parties, etc),
will be a challenging task in the years to
come.
In conclusion, recent advances in
genomics have highlighted the polygen-
ic nature of most common disorders.
The effects of these genetic variants also
need to be studied taking into account
time-dependent environmental and be-
havioural factors.5 As a consequence,
any single genetic variant has little
impact in terms of disease risk predic-
tion. Yet, polygenic risk scores in rela-
tion to continuous traits (i.e. BMI,
blood lipid, blood pressure, etc) should
stimulate public health researchers to
change paradigms and consider integra-
tion of multilayer biological data, dy-
namic designs, agnostic approaches, as
well as using quantitative measures in
assessing both exposures and outcomes
(i.e. continuum of affectedness). Such
quantitative thinking leads to a public
health model that focuses on prevention
on a continuous scale rather than just
treating cases. Looking at multivariate
continuous dimensions rather than clin-
ical diagnoses using arbitrary cut-offs
represent more powerful approaches to
decipher the complex etiological mech-
anisms leading to human diseases.
Large inter-disciplinary teams are
needed to properly design studies
and collect, store and analyse high-
throughput data. Whereas the prices of
‘omics’ data production have dramatic-
ally come down, the costs of data storage
and analysis are very high and often tend
to be underestimated. Unless studies
are not well funded, epidemiology will
not be able to assume the challenges
mentioned above. High-quality and
continuously updated education pro-
grammes are needed to ensure that
researchers and health-care
professionals are able to critically ap-
praise research findings in the ‘omics’
fields, including ‘epi-omics’.
Funding
Murielle Bochud is supported by the
Swiss School of Public Health Plus,
Nu´ria Malats by EU-FP7-PHGEN II
#2008302.
References
1 Manolio TA. Genomewide association studies
and assessment of the risk of disease. N Engl J
Med 2010;363:166–76.
2 French B, Joo J, Geller NL, et al.
Anticoagulation Through Genetics Investigators
CC. Statistical design of personalized medicine
interventions: the Clarification of Optimal
Anticoagulation through Genetics (COAG)
trial. Trials 2010;11:108.
3 Hall WD, Mathews R, Morley KI. Being
more realistic about the public health impact
of genomic medicine. PLoS Med
2010;7:e1000347.
4 Houle D, Govindaraju DR, Omholt S.
Phenomics: the next challenge. Nat Rev Genet
2010;11:855–66.
5 Ioannidis JP, Loy EY, Poulton R, et al.
Researching genetic versus nongenetic deter-
minants of disease: a comparison and proposed
unification. Sci Transl Med 2009;1:7ps8.
Murielle Bochud1, Nu´ria Malats2
1Institute of Social and Preventive Medicine,
Centre Hospitalier Universitaire Vaudois
and University of Lausanne, Lausanne,
Switzerland, 2Genetic and Molecular
Epidemiology Group, Spanish National Cancer
Research Centre (CNIO), Madrid, Spain
Correspondence: Nu´ria Malats, Grupo de
Epidemiologı´a Gene´tica y Molecular,
Programa de Gene´tica del Ca´ncer Humano,
Centro Nacional de Investigaciones
Oncolo´gicas (CNIO), Melchor Ferna´ndez
Almagro, 3, 28029-Madrid, Espan˜a.
e-mail: nuria@cnio.es
doi:10.1093/eurpub/ckq203
A European view on the future of personalised medicine in the EU
At the European Health Forum Gastein
in October 2010, personalized medicine
was presented as a new paradigm for
health care in Europe. I had the oppor-
tunity to participate in this session and
to listen to the views of my esteemed
co-participants on what can be done at
the European level to achieve imple-
mentation of personalized medicine
approaches and other emerging
technologies.
Personalized medicine is becoming an
ever more important area for the appli-
cation of genome-based information
and technologies identified under
public health genomics. The scope and
vision of public health genomics,
according to the 2005 Bellagio
Conference1 is ‘the responsible and
effective translation of genome-based
knowledge and technologies for the
benefit of population health’.
This concept encompasses both
population and individual health. It
covers prevention, treatment and care.
Genomics is clearly an area of in-
novative research that seeks to close the
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